Brian Armstrong's NewLimit Secures $435M From Founders Fund
Founders Fund-led round brings in Thrive, Greenoaks and Eli Lilly Ventures — and accelerates NewLimit's push to take its first age-reprogramming candidate into human trials in 2026.
Every Zipp story tagged #Longevity, newest first.
Founders Fund-led round brings in Thrive, Greenoaks and Eli Lilly Ventures — and accelerates NewLimit's push to take its first age-reprogramming candidate into human trials in 2026.